In8Bio
NASDAQ: INABNew York, US · Founded 2018 · Delaware corporation · 25 employees on LinkedIn
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological tumors using its DeltEx platform (allogeneic, autologous, iPSC, and genetically modified approaches). Its lead candidates include INB-400 and INB-200 for glioblastoma and INB-100 for leukemia patients undergoing bone marrow transplantation.
Founders & leadership
In8Bio was founded in 2018 by Lawrence Lamb and William Ho.
LL
Lawrence LambScientific Founder & Chief Scientific Officer
WH
William HoinCEO & Director, Co-founderFounder and CEO of IN8bio, a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological cancers through its DeltEx platform, with lead candidates including INB-400 and INB-200 for glioblastoma and INB-100 for leukemia.
KR
Kate RochlinExecutive
PM
Patrick McCallExecutive
TW
Travis WhitfillNamed on SEC filing
MB
Melissa BeelenNamed on SEC filing
TC
Thomas CirritoNamed on SEC filing
Board
ER
Emily R. FairbairnBoard director
AS
Alan S. RoemerBoard director
CE
Corinne EpperlyBoard director
JG
Jeremy GraffBoard director
LG
Luba GreenwoodBoard director
Reported raises · per SEC filings
Form D private placements$81.9M disclosed across 4 rounds · 2018–2025
▶$20.1MraisedDec 2025 · 17 investors · BiotechnologyRule 506(b)
▶$20.1MraisedDec 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Luba GreenwoodDirector
- Lawrence LambExecutive Officer
- William HoExecutive Officer, Director
- Peter BrandtDirector
- Jeremy GraffDirector
- Kate RochlinExecutive Officer
- Emily R. FairbairnDirector
- Corinne EpperlyDirector
- Alan S. RoemerDirector
- Patrick McCallExecutive Officer
- Offering amount
- $40.2M
- Amount sold
- $20.1M
- Sales commissions
- $1.2M
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.4MraisedOct 2024 · 73 investors · BiotechnologyRule 506(c)
▶$12.4MraisedOct 2024 · 73 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Travis WhitfillDirector
- Lawrence LambExecutive Officer
- Alan S. RoemerDirector
- William HoExecutive Officer, Director
- Corinne EpperlyDirector
- Kate RochlinExecutive Officer
- Jeremy GraffDirector
- Emily R. FairbairnDirector
- Patrick McCallExecutive Officer
- Luba GreenwoodDirector
- Peter BrandtDirector
- Offering amount
- $12.4M
- Amount sold
- $12.4M
- Sales commissions
- $742.8K
- Placement agents
- Newbridge Securities Corporation
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$14.4MraisedDec 2023 · 20 investors · BiotechnologyRule 506(b)
▶$14.4MraisedDec 2023 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kate RochlinExecutive Officer
- Emily FairbairnDirector
- Jeremy R. GraffDirector
- Peter BrandtDirector
- Trishna GoswamiExecutive Officer
- Corinne EpperlyDirector
- Alan S. RoemerDirector
- William HoExecutive Officer, Director
- Luba GreenwoodDirector
- Patrick McCallExecutive Officer
- Travis WhitfillDirector
- Lawrence LambExecutive Officer
- Offering amount
- $14.4M
- Amount sold
- $14.4M
- Sales commissions
- $643.5K
- Placement agents
- Cantor Fitzgerald & Co.
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedSep 2020 · 33 investors · BiotechnologyRule 506(b)
▶$35MraisedSep 2020 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Travis WhitfillDirector
- Melissa BeelenExecutive Officer
- Thomas CirritoDirector
- Larry LambExecutive Officer
- William HoExecutive Officer, Director
- Peter BrandtDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does In8Bio do?
- IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and hematological tumors using its DeltEx platform (allogeneic, autologous, iPSC, and genetically modified approaches). Its lead candidates include INB-400 and INB-200 for glioblastoma and INB-100 for leukemia patients undergoing bone marrow transplantation.
- Who founded In8Bio?
- In8Bio was founded by Lawrence Lamb, William Ho in 2018.
- How much funding has In8Bio raised?
- In8Bio has disclosed $81.9M raised across 4 rounds.
- Where is In8Bio headquartered?
- In8Bio is headquartered in New York, US.